临床试验/NCT07266207

NCT07266207已完成1 期

A Randomized, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Food Effects of ARD-885 Film-coated Tablets in Healthy Chinese Subjects and Patients With Rheumatoid Arthritis

Artivila (Shenzhen) Innovation Center, Ltd1 个研究点分布在 1 个国家目标入组 94 人开始时间: 2024年12月16日最近更新: 2025年12月5日

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 94
试验地点: 1
主要终点: Adverse Events (AE)/Severe Adverse Events (SAE)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The proposed study is a randomized, double-blind, placebo-controlled single and multiple ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetic, and food effects of ARD-885 Film-coated Tablets in healthy subjects.The entire study includes 3 parts: a single ascending dose study, a multiple ascending dose study, and a food-effect bioavailability study in healthy subjects.

详细描述

The whole study includes 3 parts: a single ascending dose study, a multiple ascending dose study, and a food-effect bioavailability study. The SAD and MAD studies are randomized, double-blinded, and placebo-controlled studies, and the FE study is a randomized, open-label, two-period, two-treatment (2×2) crossover study.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Sequential
主要目的: Treatment
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 70 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•All subjects:
•Healthy male and female subjects of any ethnic origin between the ages of 18 and
•Male and female patients with rheumatoid arthritis between the ages of 18 and
•An informed consent document signed and dated by the subject. Subjects must be willing to understand and comply with all research procedures and restrictions and be able to communicate effectively with investigators.
•A minimum body weight of 50 kg for males and 45 kg for females, with a body mass index of 18 to 28 kg/m2 for healthy subjects and 18 to 35 kg/m2 for patients with RA.
•Subject (including partner) agrees to use at least one effective contraceptive method during sexual activity with partner from screening until 3 months after dosing agrees not to participate in sperm or egg donation during the study period until 3 months after the last dosing. See Section 8.1 for specific contraceptive methods.

排除标准

•Known or suspected allergy to any component of ARD-885 Film-coated Tablets, or individuals with a hypersensitivity to allergies (multiple drug and food allergies), as determined by the investigator, and deemed unsuitable for inclusion.
•Lactating women; Women of reproductive age with menstrual disorders within 90 days before administration; Women of childbearing age who have had unprotected sexual intercourse with an opposite-sex partner in the 28 days before administration. Female subjects who are lactating or have a positive serum pregnancy result during the screening period or during the trial.
•Participated in any drug clinical trial within 90 days before administration, or the administration date of this study is still within the safety washout period specified in the previous drug clinical trial.
•Non-physiological blood loss ≥ 200 ml within 60 days before administration (including trauma, blood collection, blood donation); Or plan to donate blood during the trial or within 30 days of administration.
•Had a major disease that investigators considered clinically significant within 90 days before first administration; Have any active malignancy or history of malignancy in the 5 years prior to screening, with the exception of treated and considered cured skin squamous or basal cell carcinoma, cervical carcinoma in situ, or breast ductal carcinoma in situ.
•Had major surgery within 60 days of administration, or had any surgery within 28 days of administration.
•Infectious diseases such like fever and so on within 28 days before administration.
•Previous use of any of the drugs or treatments listed in protocol.
•Received vaccine or live attenuated vaccine within 1 month before administration, or who plan to receive the vaccine during the trial period.
•Those who smoked more than 5 pieces of tobacco or equivalent daily in the 3 months before screening, or drank ≥ 14 units of alcohol per week; Or disagree with the prohibition of smoking or alcohol during the trial; Or positive alcohol serum test during screening or baseline (Day-1).
•Those who test positive for urine drugs or have a history of drug abuse or use of drugs in the past five years.
•+Positive for Treponema pallidum antibodies, hepatitis B surface antigen, hepatitis B core antibodies, hepatitis C virus antibodies or human immunodeficiency virus antibodies.
•Those who is diagnosed as tuberculosis or have a history of non-tuberculous mycobacterial infections
•Have a serious disease of the blood system or any disease that can cause hemolysis or instability of red blood cells, such as malaria, hemolytic anemia, etc..
•At the time of screening, clinically significant gastrointestinal, liver or kidney abnormalities known abnormal which likely to affect drug intake, transport, absorption, distribution, metabolism or excretion.
•Ingested any food or beverage containing caffein, or other xanthine-rich food or food that can induce or inhibit liver metabolic enzymes and beverages made from it within 48 hours before taking the study drug, or food or beverages containing alcohol, or other factors affecting drug absorption, distribution, metabolism, excretion, etc.
•Those who Can not tolerate venous puncture blood collection or faint blood needle.
•Has special requirements for diet and cannot comply with a unified diet.
•By the investigator's decision, other factors may affect the study results and interfere with his/her participation in the study process.

研究组 & 干预措施

ARD-885 Tablets (Multiple Administration Dose, cohort B1~B3)

Experimental

ARD-885 Tablets, 25 mg/50 mg/100 mg, once a day(QD), from Day1~Day7

干预措施: ARD-885 Tablets (Drug)

ARD-885 tablet (Single Administration Dose, cohort A0~A7)

Experimental

ARD-885 Tablets, 5/10/30/60/100/150/200/250 mg，a single dose on Day1

干预措施: ARD-885 Tablets (Drug)

ARD-885 Placebo tablet (Single Ascending Dose, cohort A1~A7)

Placebo Comparator

ARD-885 Placebo tablet, a single dose on Day1

干预措施: ARD-885 Placebo Tablet (Drug)

ARD-885 Tablets (Food Effect, cohort C1~C2)

Experimental

ARD-885 tablets, 50mg, a single dose on Day1 and Day7, fed or fasted crossover

干预措施: ARD-885 Tablets (Drug)

ARD-885 Placebo Tablets (Multiple Administration Dose, cohort B1~B3)

Placebo Comparator

ARD-885 Placebo tablets, once a day(QD), from Day1~Day7

干预措施: ARD-885 Placebo Tablet (Drug)

结局指标

主要结局

Adverse Events (AE)/Severe Adverse Events (SAE)

时间窗: The first day of the first administration until 7 days after the last administration.

Safety and tolerability are assessed by the incidence of adverse events and its severity caused by the study drug during or after dose.

次要结局

PK: Cmax of ARD-885.(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PK: T1/2 of ARD-885.(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PK: Tmax of ARD-885.(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PK: AUC0-t of ARD-885.(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PK: AUC0-last of ARD-885.(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PK: AUC0-inf of ARD-885.(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PK: CL/F of ARD-885.(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PK: Css_max of ARD-885.(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PK: Tss_max of ARD-885.(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PK: RACmax of ARD-885.(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PK: Css_min of ARD-885.(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PK: AUCss_tau of ARD-885.(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PK: RAAUCtau of ARD-885(Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.)
PD: The concentration of TNF-α(blood samples were collected from 1 hour before first administration to 24 hours after the last administration.)
PD: The concentration of IL-6.(blood samples were collected from 1 hour before first administration to 24 hours after the last administration.)
PD: The concentration of IL-1β.(blood samples were collected from 1 hour before first administration to 24 hours after the last administration.)

研究者

发起方

Artivila (Shenzhen) Innovation Center, Ltd

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

招募中

1 期

A Study to Evaluate the Safety, Tolerability and PK of SK-09FSGS

NCT07267026Consun Pharmaceutical Group84

招募中

2 期

Topical Ketotifen 0.25% for Secondary Vestibulodynia

NCT07257029Center for Vulvovaginal Disorders54

招募中

1 期

Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.Eosinophilic esophagitis

2024-512722-28-00Bioprojet Pharma161

已完成

1 期

Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant after repeated oral ascending doses for 14 days, including the pitolisant effect on cardiac repolarization in healthy volunteers.

2023-503945-78-00Bioprojet Pharma75

招募中

1 期

Randomized, Double Blind, Placebo Controlled "first-in-human" Study to Assess the Safety and Tolerability of Single Ascending Intravenous Doses and Multiple Intravenous Doses of RA0127 in Healthy Young Volunteers

2023-504324-26-00Remab Therapeutics S.L.40